A new approach to control the enigmatic activity of aldose reductase.

Aldose reductase (AR) is an NADPH-dependent reductase, which acts on a variety of hydrophilic as well as hydrophobic aldehydes. It is currently defined as the first enzyme in the so-called polyol pathway, in which glucose is transformed into sorbitol by AR and then to fructose by an NAD(+)-dependent...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Antonella Del-Corso, Francesco Balestri, Elisa Di Bugno, Roberta Moschini, Mario Cappiello, Stefania Sartini, Concettina La-Motta, Federico Da-Settimo, Umberto Mura
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/cf978c944f8142b7a5fa55f15794e781
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:cf978c944f8142b7a5fa55f15794e781
record_format dspace
spelling oai:doaj.org-article:cf978c944f8142b7a5fa55f15794e7812021-11-18T08:57:09ZA new approach to control the enigmatic activity of aldose reductase.1932-620310.1371/journal.pone.0074076https://doaj.org/article/cf978c944f8142b7a5fa55f15794e7812013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24019949/?tool=EBIhttps://doaj.org/toc/1932-6203Aldose reductase (AR) is an NADPH-dependent reductase, which acts on a variety of hydrophilic as well as hydrophobic aldehydes. It is currently defined as the first enzyme in the so-called polyol pathway, in which glucose is transformed into sorbitol by AR and then to fructose by an NAD(+)-dependent dehydrogenase. An exaggerated flux of glucose through the polyol pathway (as can occur in diabetes) with the subsequent accumulation of sorbitol, was originally proposed as the basic event in the aethiology of secondary diabetic complications. For decades this has meant targeting the enzyme for a specific and strong inhibition. However, the ability of AR to reduce toxic alkenals and alkanals, which are products of oxidative stress, poses the question of whether AR might be better classified as a detoxifying enzyme, thus raising doubts as to the unequivocal advantages of inhibiting the enzyme. This paper provides evidence of the possibility for an effective intervention on AR activity through an intra-site differential inhibition. Examples of a new generation of aldose reductase "differential" inhibitors (ARDIs) are presented, which can preferentially inhibit the reduction of either hydrophilic or hydrophobic substrates. Some selected inhibitors are shown to preferentially inhibit enzyme activity on glucose or glyceraldehyde and 3-glutathionyl-4-hydroxy-nonanal, but are less effective in reducing 4-hydroxy-2-nonenal. We question the efficacy of D, L-glyceraldehyde, the substrate commonly used in in vitro inhibition AR studies, as an in vitro reference AR substrate when the aim of the investigation is to impair glucose reduction.Antonella Del-CorsoFrancesco BalestriElisa Di BugnoRoberta MoschiniMario CappielloStefania SartiniConcettina La-MottaFederico Da-SettimoUmberto MuraPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 9, p e74076 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Antonella Del-Corso
Francesco Balestri
Elisa Di Bugno
Roberta Moschini
Mario Cappiello
Stefania Sartini
Concettina La-Motta
Federico Da-Settimo
Umberto Mura
A new approach to control the enigmatic activity of aldose reductase.
description Aldose reductase (AR) is an NADPH-dependent reductase, which acts on a variety of hydrophilic as well as hydrophobic aldehydes. It is currently defined as the first enzyme in the so-called polyol pathway, in which glucose is transformed into sorbitol by AR and then to fructose by an NAD(+)-dependent dehydrogenase. An exaggerated flux of glucose through the polyol pathway (as can occur in diabetes) with the subsequent accumulation of sorbitol, was originally proposed as the basic event in the aethiology of secondary diabetic complications. For decades this has meant targeting the enzyme for a specific and strong inhibition. However, the ability of AR to reduce toxic alkenals and alkanals, which are products of oxidative stress, poses the question of whether AR might be better classified as a detoxifying enzyme, thus raising doubts as to the unequivocal advantages of inhibiting the enzyme. This paper provides evidence of the possibility for an effective intervention on AR activity through an intra-site differential inhibition. Examples of a new generation of aldose reductase "differential" inhibitors (ARDIs) are presented, which can preferentially inhibit the reduction of either hydrophilic or hydrophobic substrates. Some selected inhibitors are shown to preferentially inhibit enzyme activity on glucose or glyceraldehyde and 3-glutathionyl-4-hydroxy-nonanal, but are less effective in reducing 4-hydroxy-2-nonenal. We question the efficacy of D, L-glyceraldehyde, the substrate commonly used in in vitro inhibition AR studies, as an in vitro reference AR substrate when the aim of the investigation is to impair glucose reduction.
format article
author Antonella Del-Corso
Francesco Balestri
Elisa Di Bugno
Roberta Moschini
Mario Cappiello
Stefania Sartini
Concettina La-Motta
Federico Da-Settimo
Umberto Mura
author_facet Antonella Del-Corso
Francesco Balestri
Elisa Di Bugno
Roberta Moschini
Mario Cappiello
Stefania Sartini
Concettina La-Motta
Federico Da-Settimo
Umberto Mura
author_sort Antonella Del-Corso
title A new approach to control the enigmatic activity of aldose reductase.
title_short A new approach to control the enigmatic activity of aldose reductase.
title_full A new approach to control the enigmatic activity of aldose reductase.
title_fullStr A new approach to control the enigmatic activity of aldose reductase.
title_full_unstemmed A new approach to control the enigmatic activity of aldose reductase.
title_sort new approach to control the enigmatic activity of aldose reductase.
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/cf978c944f8142b7a5fa55f15794e781
work_keys_str_mv AT antonelladelcorso anewapproachtocontroltheenigmaticactivityofaldosereductase
AT francescobalestri anewapproachtocontroltheenigmaticactivityofaldosereductase
AT elisadibugno anewapproachtocontroltheenigmaticactivityofaldosereductase
AT robertamoschini anewapproachtocontroltheenigmaticactivityofaldosereductase
AT mariocappiello anewapproachtocontroltheenigmaticactivityofaldosereductase
AT stefaniasartini anewapproachtocontroltheenigmaticactivityofaldosereductase
AT concettinalamotta anewapproachtocontroltheenigmaticactivityofaldosereductase
AT federicodasettimo anewapproachtocontroltheenigmaticactivityofaldosereductase
AT umbertomura anewapproachtocontroltheenigmaticactivityofaldosereductase
AT antonelladelcorso newapproachtocontroltheenigmaticactivityofaldosereductase
AT francescobalestri newapproachtocontroltheenigmaticactivityofaldosereductase
AT elisadibugno newapproachtocontroltheenigmaticactivityofaldosereductase
AT robertamoschini newapproachtocontroltheenigmaticactivityofaldosereductase
AT mariocappiello newapproachtocontroltheenigmaticactivityofaldosereductase
AT stefaniasartini newapproachtocontroltheenigmaticactivityofaldosereductase
AT concettinalamotta newapproachtocontroltheenigmaticactivityofaldosereductase
AT federicodasettimo newapproachtocontroltheenigmaticactivityofaldosereductase
AT umbertomura newapproachtocontroltheenigmaticactivityofaldosereductase
_version_ 1718421111077601280